Search for drugs:
Typing the drug name to query
BALOXAVIR MARBOXIL
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- At twice the expected exposure from recommended dosing, XOFLUZA did not prolong the QTc interval.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
1
24091
Other ADRs
2920
38378667
Odds Ratio = 0.546
Drug Property Information
ATC Code(s):
- J05AX25 - baloxavir marboxil
- J05AX - Other antivirals
- J05A - DIRECT ACTING ANTIVIRALS
- J05 - ANTIVIRALS FOR SYSTEMIC USE
- J - ANTIINFECTIVES FOR SYSTEMIC USE
Active Ingredient:BALOXAVIR MARBOXIL
Active Ingredient UNII:505CXM6OHG
Drugbank ID:DB13997
PubChem Compound:N/ADIR Classification
CTD ID:C000628402
CAS Number:1985606-14-1
Dosage Form(s):tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
- 40.0 mg/day J05AX25
Chemical Structure: 
SMILE Code:
[H][C@@]12COCCN1C(=O)C1=C(OCOC(=O)OC)C(=O)C=CN1N2[C@H]1C2=CC=C(F)C(F)=C2CSC2=CC=CC=C12
[H][C@@]12COCCN1C(=O)C1=C(OCOC(=O)OC)C(=O)C=CN1N2[C@H]1C2=CC=C(F)C(F)=C2CSC2=CC=CC=C12
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.